宫颈阴道微生物组、BRCA1突变状态与卵巢癌风险的病例对照研究
该病例对照研究在捷克、德国、意大利、挪威和英国纳入18-87岁女性,分析宫颈阴道微生物组与卵巢癌及BRCA1突变状态的关联。研究发现,年轻(<50岁)卵巢癌患者和BRCA1突变携带者中,以非乳酸杆菌为主的社区型O微生物组比例显著高于同龄对照,且年龄越轻关联越强。
要点
- 年龄越轻,社区型O微生物组与卵巢癌或BRCA1突变状态的关联越强。
核心结论
- 卵巢癌的存在或已知影响风险的因素(年龄和BRCA1胚系突变)与宫颈阴道社区型O微生物组显著相关。
研究设计与样本
- 在捷克、德国、意大利、挪威和英国进行的病例对照研究,纳入18-87岁女性,分卵巢癌集(n=360)和BRCA集(n=220)。
- 使用ThinPrep系统采集宫颈阴道样本,进行16S rRNA基因测序,计算乳酸杆菌物种比例,并将样本分为社区型L(乳酸杆菌≥50%)和社区型O(乳酸杆菌<50%)。
- 采用逻辑回归模型(带偏倚减少方法)评估BRCA1状态和卵巢癌状态与宫颈阴道微生物组社区类型的调整关联。
关键数值与推荐
- 社区型L定义为乳酸杆菌占所存在物种的至少50%,社区型O定义为乳酸杆菌占所存在物种的不到50%。
- 卵巢癌集:≥50岁女性中社区型O患病率为81/133(61%)卵巢癌病例和84/142(59%)健康对照;<50岁女性中为23/43(53%)病例和12/42(29%)对照。
临床怎么用
- 对于年轻女性,尤其是BRCA1突变携带者,宫颈阴道社区型O微生物组可能与卵巢癌风险相关,需进一步研究。
- 通过阴道栓剂等方式恢复社区型L微生物组是否可改变上生殖道微生物组成并降低卵巢癌发病率,尚需研究。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various factors-including age, family history, inflammation, reproductive factors, and tubal ligation-modulate the risk of ovarian cancer. In this study, our aim was to establish whether women with, or at risk of developing, ovarian cancer have an imbalanced cervicovaginal microbiome. METHODS: We did a case-control study in two sets of women aged 18-87 years in the Czech Republic, Germany, Italy, Norway, and the UK. The ovarian cancer set comprised women with epithelial ovarian cancer and controls (both healthy controls and those diagnosed with benign gynaecological conditions). The BRCA set comprised women with a BRCA1 mutation but without ovarian cancer and controls who were wild type for BRCA1 and BRCA2 (both healthy controls and those with benign gynaecological conditions). Cervicovaginal samples were gathered from all participants with the ThinPrep system and then underwent 16S rRNA gene sequencing. For each sample, we calculated the proportion of lactobacilli species (ie, Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, and Lactobacillus jensenii), which are essential for the generation of a protective low vaginal pH, in the cervicovaginal microbiota. We grouped samples into those in which lactobacilli accounted for at least 50% of the species present (community type L) and those in which lactobacilli accounted for less than 50% of the species present (community type O). We assessed the adjusted association between BRCA1 status and ovarian cancer status and cervicovaginal microbiota community type, using a logistic regression model with a bias reduction method. FINDINGS: Participants were recruited between Jan 2, 2016, and July 21, 2018. The ovarian cancer set (n=360) comprised 176 women with epithelial ovarian cancer, 115 healthy controls and 69 controls with benign gynaecological conditions. The BRCA set (n=220) included 109 women with BRCA1 mutations, 97 healthy controls wild type for BRCA1 and BRCA2 and 14 controls with a benign gynaecological condition wild type for BRCA1 and BRCA2. On the basis of two-dimensional density plots, receiver-operating characteristic curve analysis, and age thresholds used previously, we divided the cohort into those younger than 50 years and those aged 50 years or older. In the ovarian cancer set, women aged 50 years or older had a higher prevalence of community type O microbiota (81 [61%] of 133 ovarian cancer cases and 84 [59%] of 142 healthy controls) than those younger than 50 years (23 [53%] of 43 cases and 12 [29%] of 42 controls). In the ovarian cancer set, women younger than 50 years with ovarian cancer had a significantly higher prevalence of community type O microbiota than did age-matched controls under a logistic regression model with bias correction (odds ratio [OR] 2·80 [95% CI 1·17-6·94]; p=0·020). In the BRCA set, women with BRCA1 mutations younger than 50 years were also more likely to have community type O microbiota than age-matched controls (OR 2·79 [95% CI 1·25-6·68]; p=0·012), after adjustment for pregnancy (ever). This risk was increased further if more than one first-degree family member was affected by any cancer (OR 5·26 [95% CI 1·83-15·30]; p=0·0022). In both sets, we noted that the younger the participants, the stronger the association between community type O microbiota and ovarian cancer or BRCA1 mutation status (eg, OR for community type O for cases aged <40 years in the ovarian cancer set 7·00 [95% CI 1·27-51·44], p=0·025; OR for community type O for BRCA1 mutation carriers aged <35 years in the BRCA set 4·40 [1·14-24·36], p=0·031). INTERPRETATION: The presence of ovarian cancer, or factors known to affect risk for the disease (ie, age and BRCA1 germline mutations), were significantly associated with having a community type O cervicovaginal microbiota. Whether re-instatement of a community type L microbiome by using, for example, vaginal suppositories containing live lactobacilli, would alter the microbiomial composition higher up in the female genital tract and in the fallopian tubes (the site of origin of high-grade serous ovarian cancer), and whether such changes could translate into a reduced incidence of ovarian cancer, needs to be investigated. FUNDING: EU Horizon 2020 Research and Innovation Programme, EU Horizon 2020 European Research Council Programme, and The Eve Appeal.
引用
- Nené NR, Reisel D, Leimbach A, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncol. 2019. PMID: 31300207. doi:10.1016/S1470-2045(19)30340-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。